Lab Worker

An incubator supporting UK SMEs in the transformation of chemistry into the digital domain.

Learn more about the iDMT

About iDMT

The mission of the Innovation Centre in Digital Molecular Technologies (iDMT) is to support UK SMEs in:

(i) Establishing new products and services to support the digital transformation of the molecular industries, and

(ii) Exploiting the power of AI and machine learning in molecular sciences, technologies and products.

The iDMT is an open innovation research centre, co-funded by the University of Cambridge, AstraZeneca, Shionogi and European Regional Development Fund (ERDF). Find out more about our partners >

The iDMT is located in the Yusuf Hamied Department of Chemistry, Lensfield Road, Cambridge. Our facilities will include two refurbished labs and offices to host collaborative projects. Contact us >

Research Areas

We work with SMEs to help them develop new products and services to serve the emerging digital chemistry market. The iDMT undertakes collaborative research projects in three key ditigal molecular technology areas:

Artificial intelligence in molecular technologies

Robotic equipment for chemical synthesis

Algorithms for digital process development


Our business support will include access to lab space and a collaborative research environment; participation in joint development with leading researchers from academia and the pharmaceutical industry; and access to equipment, materials and computational resources.

University of Cambridge

The University is one of the world’s oldest universities and leading academic centres, and a self-governed community of scholars. The University is a home of 20,000 students from all walks of life and all corners of the world, over 11,000 staff, 31 Colleges and 150 Departments, Faculties, Schools and other institutions.

European Regional Development Fund

The ERDF aims to strengthen economic and social cohesion in the European Union by correcting imbalances between its regions.


AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.


Shionogi is a major research-driven pharmaceutical company dedicated to placing the highest value on patients based on its corporate philosophy of “supply the best possible medicine to protect the health and wellbeing of the patients we serve”. We recently announced our 2030 vision “Building Innovation Platforms to Shape the Future of Healthcare” and the medium-term business plan “STS2030” for the realization of the vision.


iDMT Team

The iDMT team is composed of:

  • World leading experts from the University of Cambridge in fields including sustainable engineering, probabilistic machine learning and chemical synthesis.

  • Insights from industrial partners from global pharmaceutical companies.



Professor Alexei Lapkin


AstraZeneca Management Board Member

Dr Clive Green

Shionogi Management Board Member

Dr Masami Takayama


Research Lead

Dr Alpha Lee


University of Cambridge Researcher

Dr Danielo Russo

PhD Student

Joseph Phelps

PhD Student

Daniel Wigh



Professor Matthew Gaunt

AstraZeneca Management Board Member

Dr Michael Kossenjans


Kerstin Enright


Research Lead

Dr Sebastian Ahnert

Shionogi Researcher

Dr Akihiro Takada

PhD Student

Alexander Pomberger


Project Manager

Shionogi Management Board Member

Dr Kenji Yamawaki


Research Lead

Professor Jonathan Goodman


Research Lead

Dr Jose Miguel Hernandez Lobato

PhD Student

Antonio Pedrina

PhD Student

Milo Smith


MAB4 Conference

6 Jul 21 | Online

iDMT Grand Opening


Yusuf Hamied Department of Chemistry

University of Cambridge

Lensfield Road

Cambridge, England